AEON

AEON Biopharma Inc

AMEX

Add Alert

AEON

AEON Biopharma Inc

AMEX

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

DewDiligence PremiumMember

04/01/24 2:38 PM

Post #16

Re: #15: @trglaa - What happened here today?

Dilution from the redemption of warrants:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001837607/000183760724000017/aeon-20240329x8k.htm

trglaa

04/01/24 2:31 PM

Post #15

What happened here today?

DewDiligence PremiumMember

03/30/24 3:39 PM

Post #14

AEON 4Q23 financials:

https://www.globenewswire.com/news-release/2024/03/29/2854830/0/en/AEON-Biopharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html

DewDiligence PremiumMember

03/19/24 4:47 PM

Post #13

Re: #9: @DewDiligence - AEON phase-2 trial_in episodic migraine misses_ primary_endpoint:

AEON updates plans for migraine program:

https://finance.yahoo.com/news/aeon-biopharma-announces-clinical-productive-203000664.html

DewDiligence PremiumMember

03/19/24 4:46 PM

Post #12

Re: #10: @DewDiligence - AEON needs to raise cash very soon:

AEON sells $15M of convertible debt to_supplier, Daewoong:

https://finance.yahoo.com/news/aeon-biopharma-announces-15-million-202900910.html

DewDiligence PremiumMember

01/18/24 6:33 PM

Post #11

Re: #9: @DewDiligence - AEON phase-2 trial_in episodic migraine misses_ primary_endpoint:

AEON presents phase-2 data in cervical dystonia:

https://finance.yahoo.com/news/aeon-biopharma-presents-positive-clinical-210500488.html

CD had been AEON’s lead indication for ABP-450, but AEON changed gears and made episodic migraine the lead indication after RVNC reported Daxxify data in CD (https://www.sec.gov/Archives/edgar/data/1837607/000110465923063774/tm2316532d1_ex99-1.htm ). When AEON’s phase-2 in episodic migraine failed in Oct 2023 (#msg-173058579), CD again became the lead indication by default.

The above PR also includes preclinical data for ABP-450 in PTSD (!?).

AEON needs to raise a significant amount of cash to conduct a phase-3 trial in any indication (#msg-173211412).

Reminder: ABP-450, sourced from Korea’s Daewoong, is the exact same toxin as EOLS’ Jeuveau. See #msg-172274907 for background info.

DewDiligence PremiumMember

11/13/23 11:47 AM

Post #10

Re: #9: @DewDiligence - AEON phase-2 trial_in episodic migraine misses_ primary_endpoint:

AEON needs to raise cash very soon:

https://www.globenewswire.com/news-release/2023/11/13/2779046/0/en/AEON-Biopharma-Reports-Third-Quarter-2023-Financial-Results.html

The Company reported cash, cash equivalents and investments were approximately $16.2 million as of September 30, 2023.

The Company believes its cash, cash equivalents and investments will be sufficient to fund its planned clinical studies, as well as support corporate operations into mid-December 2023.

No quarterly CC.

DewDiligence PremiumMember

10/19/23 7:33 PM

Post #9

AEON phase-2 trial_in episodic migraine misses_ primary_endpoint:

https://finance.yahoo.com/news/aeon-biopharma-announces-topline-results-200500504.html

On the primary endpoint, the topline data showed ABP-450 had a treatment effect with mean reductions in MMD [monthly migraine days] of 4.8 days at the 150U dose (n = 99) and 5.0 days at the 195U dose (n = 108), compared to only 4.2 days in placebo (n = 98) at weeks 21-24, but did not meet statistical significance…

Episodic migraine is (was) ABP-450’s lead indication. The lead indication had previously been cervical dystonia, but AEON backed off from CD due, presumably, to RVNC’s stellar dataset in that indication.

AEON’s ABP-450 is the exact same drug as EOLS’ Jeuveau. Please see #msg-172274907 for related info.

DewDiligence PremiumMember

08/30/23 4:10 PM

Post #8

Re: #7: @trglaa - Nice run today.

AEON's trading liquidity is so low it doesn't take much to move the share price. Today's news was actually minor in the overall scheme of things insofar as AEON has apparently put the brakes on its clinical program in cervical dystonia in order to pursue episodic migraine.

trglaa

08/30/23 4:05 PM

Post #7

Nice run today.

DewDiligence PremiumMember

08/29/23 12:56 PM

Post #6

AEON presents phase-2 data in cervical dystonia:

https://finance.yahoo.com/news/aeon-biopharma-presents-positive-results-120000687.html

Note: Episodic migraine, rather than cervical dystonia, is now AEON’s lead indication for ABP-450. This change is presumably due to RVNC’s robust data in cervical dystonia and the recent FDA approval of Daxxify for CD.

See #msg-172274963 for related info.

DewDiligence PremiumMember

07/24/23 10:59 AM

Post #5

AEON's initial press release:

https://finance.yahoo.com/news/aeon-biopharma-announces-closing-business-110000037.html

TESLA777

07/23/23 3:07 PM

Post #4

Re: #1: @DewDiligence - AEON Biopharma begins_trading_7/24/23_under_the_symbol, AEON, following the closing of

$AEON This is the one Im watching/trading tomorrow....GLTY......

DewDiligence PremiumMember

07/21/23 5:57 PM

Post #3

AEON’s corporate slide presentation:

https://www.sec.gov/Archives/edgar/data/1837607/000110465923063774/tm2316532d1_ex99-1.htm

Notably, AEON’s lead indication is now episodic migraine. AEON’s lead indication was previously cervical dystonia, so it seems reasonable to surmise that RVNC’s stellar data in CD altered AEON’s plans.

DewDiligence PremiumMember

07/21/23 5:53 PM

Post #2

AEON seeks_to_compete_in_the therapeutic—(rather than aesthetic)—market_for botulinum toxin. AEON's botulinum toxin, ABP-450 is the exact same product as EOLS’ Jeuveau, sourced from Korea's Daewoong.